Five years after Epic's sepsis-prediction algorithm flopped in hospitals nationwide, startups like Bayesian Health, freshly FDA-cleared, are testing whether they can beat the EHR giant at its own game.
Novo Nordisk named Amazon Web Services its preferred cloud and AI partner on August 10, opening a co-innovation hub in London where AWS engineers work inside the drugmaker's own research teams to speed up target discovery and molecule design.
HCA Healthcare says AI-driven automation of billing and clinical documentation will save roughly $400 million in 2026 — and UBS thinks the real number could reach $700 million as the technology matures across its 170+ hospitals.
UnitedHealth is spending $3 billion on AI across 2026-2027, with tools like PreCheck cutting prior-authorization approvals from 8 hours to under 30 seconds — even as Congress and lawsuits keep scrutinizing the company's use of algorithms in coverage decisions.
A newly funded NIH project led by University of Michigan researchers is building risk-sensitive AI to prevent pharmacy dispensing errors, which contribute to an estimated 1.5 million emergency room visits annually in the US.
India's health ministry launched JANANI, a nationwide digital platform with QR-coded health cards and automated risk alerts, tracking over 3 million pregnant women within its first months to close maternal care continuity gaps.
Butterfly Network's newly FDA-cleared handheld AI ultrasound tool estimates fetal gestational age in under two minutes without a trained sonographer, part of a broader 2026 push to bring prenatal imaging to underserved and emergency settings.
Insilico Medicine has advanced rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis, into a Phase III trial of 320 patients, making it one of only a handful of AI-discovered therapeutics to reach late-stage testing.
Twelve major U.S. health systems serving nearly 20 million patients annually have formed the Diagnostic AI Consortium with Aidoc to jointly test and govern diagnostic AI tools, with initial results expected in 2027.
The FDA has scheduled a September 23, 2026 advisory panel review of Grail's Galleri blood test, an AI-driven screen for more than 50 cancer types, despite a UK trial earlier this year that missed its primary endpoint.